About NIMGenetics
NIMGenetics is a Healthcare company based in Madrid (Spain) founded in 2007, and was acquired by Veritas Genetics in January 2025. Diagnostic solutions are developed using microarray and next-generation sequencing technologies. NIMGenetics has raised $7.63 million across 2 funding rounds from investors including Veritas Genetics, European Union and Apposite Capital. NIMGenetics has completed 1 acquisition, including Gene Predictis. NIMGenetics offers products and services including TrisoNIM, GenoNIM, ExoNIM, and NIMSeq. Its focus areas include Diversified Diagnostics, Life Sciences, Clinical Genomics and Sequencing Based.
Company details
Diagnostic solutions based on microarray and next-generation sequencing technologies. The company develops products for both the clinical and research markets. It has three product families for clinical diagnostics TRISONIM, a non-invasive prenatal test for the most commonly diagnosed fetal abnormalities KARYONIM, a range of products for invasive fetal and neonatal testing for chromosomal abnormalities and ONCONIM, which contains one test for BRCA testing, and two gene panels for enabling precision medicine in cancer patients. In addition, NIMGenetics has NIMFISH which is a range of customized FISH probes and EXONIM for whole exome sequencing. NIMGenetics is certified by Life Technologies (now ThermoFisher) for exome sequencing.
- Headquarters Madrid, Spain
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nimgenetics.com
- Social LinkedIn X Facebook YouTube
- Acquired by Veritas Genetics (Jan 2025)
- Total Equity Funding$7.63M (USD)
in 2 rounds
- Latest Funding Round$7.63M (USD), Series A
May 2017
- InvestorsVeritas Genetics
& 2 more
- Investments & Acquisitions
- Acquired byVeritas Genetics
(Jan 2025)
Products & Services of NIMGenetics
NIMGenetics offers a comprehensive portfolio of products and services, including TrisoNIM, GenoNIM, ExoNIM, and NIMSeq.
Detects aneuploidies and deletions for prenatal diagnostics.
Enables genomic analysis for various medical applications.
Provides complete exome analysis for genetic disorders.
Offers sequencing services for prenatal and postnatal testing.
Apps and channels of NIMGenetics
its YouTube channel NIMGenetics Diagnóstico Genético has 76 subscribers and 30 videos.
Videos from NIMGenetics
The most watched videos on NIMGenetics's YouTube channel, NIMGenetics Diagnóstico Genético (76 subscribers). Click a video to play it here.
More on NIMGenetics Diagnóstico Genético.
Funding Insights of NIMGenetics
NIMGenetics has successfully raised a total of $7.63M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $7.63 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.63M
- Total Rounds 2
- Last Round Series A — $7.63M
- First Round $260,909
(Jan 2017)
- Investors Count 2
All 2 funding rounds of NIMGenetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $7.63M | Series A | – | Apposite Capital | – |
| Jan 2017 | $260,909 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in NIMGenetics
NIMGenetics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Veritas Genetics, European Union and Apposite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare impact investments are managed by Apposite Capital. | appositecapital.com | London, United Kingdom | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Genetic testing products for health risks and traits are offered. | 2014 | veritasgenetics.com | Danvers, United States |
Investor details for NIMGenetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NIMGenetics
8 people are tracked at NIMGenetics (1 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Miguel Del Cerro | Director de Recursos Humanos y Comunicación Corporativa | Leadership |
Salomé Jackson | Marketing Research | Team |
Esther Martin Palomino | Talent Manager | Team |
Mónica Bustillo Salcines | Controller Financiero Senior | Team |
Sandra Paredes Hernández | Marketing Assistant | Team |
Maria Calvente Garcia | Cytogenomics Laboratory Manager | Team |
Paula Llabata Babiano, PhD | Research And Development Specialist | Team |
Laura Serrano Castro | Facultativo Del Laboratorio De Cribado Prenatal No Invasivo | Team |
Complete people profiles for NIMGenetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NIMGenetics
NIMGenetics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Gene Predictis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Genomic tests are developed for personalized medicine risks. | genepredictis.com | Lausanne, Switzerland | 0 | Feb 2023 | •••• |
Complete acquisition details for NIMGenetics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of NIMGenetics
5 dated milestones of NIMGenetics across 18 years, from founding to its latest funding, stage changes and deals.
- Founded NIMGenetics is founded.
- Funding First funding round of $261K.
- Funding Latest funding round, Series A, of $7.6M.
- Acquisition Acquires Gene Predictis.
- Exit Acquired by Veritas Genetics.
Web traffic of NIMGenetics
The website of NIMGenetics (nimgenetics.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 46% vs previous month
Websites whose visitors overlap most with NIMGenetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
labgenetics.es | labgenetics.es | 100% | #4,624,133 | – | |
dravetfoundation.eu | dravetfoundation.eu | 96% | #2,199,155 | – | |
grupovivo.life | grupovivo.life | 93% | #2,245,967 | – | |
| healthincode.com | 92% | 26.5K | #1,123,845 | View details | |
operarme.es | operarme.es | 85% | #334,585 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for NIMGenetics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nimgenetics
Complete news archive for NIMGenetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NIMGenetics
NIMGenetics was founded in 2007 and raised its 1st funding round 10 years after it was founded.
NIMGenetics is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
NIMGenetics is a funded company, having raised a total of $7.63M across 2 funding rounds to date. The company's 1st funding round was a Grant of $260.91K, raised on Jan 2017.
Diagnostic solutions based on microarray and next-generation sequencing technologies. The company develops products for both the clinical and research markets. It has three product families for clinical diagnostics TRISONIM, a non-invasive prenatal test for the most commonly diagnosed fetal abnormalities KARYONIM, a range of products for invasive fetal and neonatal testing for chromosomal abnormalities and ONCONIM, which contains one test for BRCA testing, and two gene panels for enabling precision medicine in cancer patients. In addition, NIMGenetics has NIMFISH which is a range of customized FISH probes and EXONIM for whole exome sequencing. NIMGenetics is certified by Life Technologies (now ThermoFisher) for exome sequencing.
NIMGenetics offers TrisoNIM, GenoNIM, ExoNIM, and NIMSeq.
NIMGenetics has made 1 acquisition, including Gene Predictis.
NIMGenetics has 3 investors. Key investors include Veritas Genetics, European Union, and Apposite Capital.
Yes. NIMGenetics was acquired by Veritas Genetics in January 2025.